Lymphoplasmacytic Lymphoma Clinical Trials

53 clinical trials for Lymphoplasmacytic Lymphoma across international registries, including 15 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas — RECRUITING · PHASE1
• Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) — RECRUITING
• Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma — RECRUITING · PHASE2
• Combating Cancer-Related Fatigue: A Personalized Supportive Care Program — RECRUITING · NA
• Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders — RECRUITING · PHASE2
• Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma — RECRUITING · PHASE1
• A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) — RECRUITING · PHASE2
• 64Cu-LLP2A for Imaging Hematologic Malignancies — RECRUITING · PHASE1
• Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies — RECRUITING · PHASE2
• Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma — RECRUITING · PHASE1
• Study of SGR-1505 in Mature B-Cell Neoplasms — RECRUITING · PHASE1
• Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas — RECRUITING · PHASE2
• A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia — RECRUITING · PHASE2
• Watch and Wait or Worry and Wait in Indolent Lymphoma — RECRUITING
• Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia — RECRUITING · PHASE2
• Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) — ACTIVE_NOT_RECRUITING · PHASE2
• Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE2
• Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma — COMPLETED · PHASE1
• Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors — NOT_YET_RECRUITING · NA
• Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases — TERMINATED · NA
• Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T — COMPLETED · PHASE1
• Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom — ACTIVE_NOT_RECRUITING · PHASE2
• Trial Evaluating MGTA-456 in Patients With High-Risk Malignancy — ACTIVE_NOT_RECRUITING · PHASE2
• Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma — ACTIVE_NOT_RECRUITING · PHASE1
• Reduced Intensity Flu/Mel/TBI Conditioning for HAPLO HCT Patients With Hematologic Malignancies — COMPLETED · PHASE2
• UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep — COMPLETED · PHASE2
• 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation — COMPLETED · PHASE2
• Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease — COMPLETED · PHASE2
• TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin Lymphomas — COMPLETED · PHASE1
• CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies — COMPLETED · PHASE1
• A Phase Ib Study of YY-20394 in Participants With B-cell Hematologic Malignancies — COMPLETED · PHASE1
• A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies — COMPLETED · PHASE1
• Immune Responses to COVID-19 Vaccination in Lymphoma Patients — COMPLETED
• Allo HSCT Using RIC for Hematological Diseases — COMPLETED · PHASE2
• Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• Oral Clofarabine for Relapsed/Refractory Non-Hodgkin Lymphoma — COMPLETED · PHASE1
• HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL — WITHDRAWN · PHASE1
• Ph I Trial of NAM NK Cells and IL-2 for Adult Pts With MM and NHL — COMPLETED · PHASE1
• Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Japanese Participants With Relapsed or Refractory Indolent B-Cell Non-Hodgkin Lymphomas (iNHL) or Chronic Lymphocytic Leukemia (CLL) — COMPLETED · PHASE1
• Pacritinib in Relapsed/Refractory Lymphoproliferative Disorders — TERMINATED · PHASE1
• Safety and Tolerability of HSC835 in Patients With Hematological Malignancies — COMPLETED · PHASE1
• Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies — TERMINATED · PHASE2
• Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma — COMPLETED · NA
• Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas — COMPLETED · PHASE2
• T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies — WITHDRAWN · PHASE1
• Study of VTD in Waldenstrom's Macroglobulinemia — OTHER · PHASE2
• First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. — COMPLETED · PHASE3
• Imexon for Relapsed Follicular and Aggressive Lymphomas — COMPLETED · PHASE2
• Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia — COMPLETED · PHASE3

Refine this search